CoChat

Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH

Open access
Boursier, J., Anty, R., Vonghia, L., Moal, V., Vanwolleghem, T., Canivet, C. M., Michalak, S., Bonnafous, S., Michielsen, P., Oberti, F., Iannelli, A., Van Gaal, L., Patouraux, S., Blanchet, O., Verrijken, A., Gual, P., Rousselet, M.‐C., Driessen, A., Hunault, G., Bertrais, S., Tran, A., Calès, P., Francque, S. · 2018 · Alimentary Pharmacology & Therapeutics
Cited by 79

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Summary: Background: The composite histological endpoint comprising nonalcoholic steatohepatitis (NASH) and NAFLD activity score ≥4 and advanced fibrosis (F ≥ 2) (“fibrotic NASH”) is becoming an important diagnostic target in NAFLD: it is currently used to select patients for inclusion in phase III therapeutic trials and will ultimately be used to indicate treatment in clinical practice once the new drugs are approved. Aim: To develop a new blood test specifically dedicated for this new diagnostic target of interest. Methods: Eight Hundred and forty‐six biopsy‐proven NAFLD patients from three centres (Angers, Nice, Antwerp) were randomised into derivation and validation sets. Results: The blood fibrosis tests BARD, NFS and FIB 4 had poor accuracy for fibrotic NASH with respective AUROC: 0.566 ± 0.023, 0.654 ± 0.023, 0.732 ± 0.021. In the derivation set, fibrotic NASH was independently predicted by AST, HOMA and CK 18; all three were combined in the new blood test MACK‐3 (hoMa, Ast, CK18) for which 90% sensitivity and 95% specificity cut‐offs were calculated. In the validation set, MACK‐3 had a significantly higher AUROC (0.847 ± 0.030, P ≤ 0.002) than blood fibrosis tests. Using liver biopsy in the grey zone between the two cut‐offs (36.0% of the patients), MACK‐3 provided excellent accuracy for the diagnosis of fibrotic NASH with 93.3% well‐classified patients, sensitivity: 90.0%, specificity: 94.2%, positive predictive value: 81.8% and negative predictive value: 97.0%. Conclusion: The new blood test MACK‐3 accurately diagnoses fibrotic NASH. This new test will facilitate patient screening and inclusion in NAFLD therapeutic trials and will enable the identification of patients who will benefit from the treatments once approved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.14621

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 79

Metadata

Authors
Boursier, J., Anty, R., Vonghia, L., Moal, V., Vanwolleghem, T., Canivet, C. M., Michalak, S., Bonnafous, S., Michielsen, P., Oberti, F., Iannelli, A., Van Gaal, L., Patouraux, S., Blanchet, O., Verrijken, A., Gual, P., Rousselet, M. ‐., Driessen, A., Hunault, G., Bertrais, S., Tran, A., Calès, P., & Francque, S.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2018-03-25
Volume
47
Issue
10
Pages
1387-1396
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2789288161
Cited by
79
References
12
FWCI
4.94
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH. https://app.cochat.ai/papers/10.1111/apt.14621
The paper
Boursier, J., Anty, R., Vonghia, L., Moal, V., Vanwolleghem, T., Canivet, C. M., Michalak, S., Bonnafous, S., Michielsen, P., Oberti, F., Iannelli, A., Van Gaal, L., Patouraux, S., Blanchet, O., Verrijken, A., Gual, P., Rousselet, M. ‐., Driessen, A., Hunault, G., . . . Francque, S. (2018). Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14621

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.